Objective To investigate the effects of Qili-Qiangxin capsule on cardiac and pulmonary functions in heart failure patients with chronic pulmonary heart disease. Methods A total of 64 heart failure patients with chronic pulmonary heart disease were divided into two groups with the method of random sampling: a treatment group (33 patients) and a control group (31 patients). The patients in the control group received conventional treatment, those in the control group received Qili-Qiangxin capsule on this basis the treatment group for 7 days. The changes of the cardiac and pulmonary functions, and plasma N-terminal pro B-type natriuretic peptide (NT-proBNP) were compared between two groups. Results The total effective rate in the treatment group was significantly higher than that of the control group (90.90% vs. 77.42%; χ2=3.908, P<0.05). There were significant difference between two groups in left ventricular ejection fraction (50.73% ± 7.23%vs. 45.22%± 6.36%;t=3.229, P=0.002), stroke volume (63.64 ± 8.38 ml vs. 56.73 ± 8.15 ml;t=3.341, P=0.001), right ventricular end-diastolic diameter (48.39 ±5.56 mm vs. 52.61 ± 6.95 mm; t=2.690, P=0.009), mean pulmonary arterial pressure (21.73 ± 5.78 mmHg vs. 27.26 ± 6.16 mmHg; t=3.705, P=0.001), plasma NT-proBNP level (535.73 ± 175.78 pg/ml vs. 831.26 ± 228.26 pg/ml; t=5.824, P=0.000), forced expiratory volume in first second (60.32% ± 5.56% vs. 48.61% ± 4.67%; t=9.093, P=0.000), percentage of forced expiratory volume in first second to forced vital capacity (66.73%± 5.78%vs. 58.26%± 5.34%;t=6.078, P=0.000), arterial oxygen saturation (96.73%± 5.78%vs. 93.26%± 5.26%;t=2.507, P=0.015), arterial partial pressure of oxygen (82.73 ± 16.78 mmHg vs. 67.26 ± 13.26 mmHg;t=4.075, P=0.000) arterial partial pressure of carbon dioxide (46.73 ± 8.78 mmHg vs. 54.26 ± 9.26 mmHg; t=3.339, P=0.00). Conclusion Qili-Qiangxin capsule can improve cardiac and pulmonary functions in heart failure patients with chronic pulmonary heart disease.

Evidence-based medicine(EBM) emphasizes that the clinical practice should be based on the combination of the best available clinical evidence,medical experiences and patient desire to cope with the demand of medical decision-making.Guidelines for good clinical(research) practice,conduct of more trials as multicentre trials,and the cochran collaboration may all help apply the best research evidence to clinical practice.China is challenged by variety of health problems.The implementation of EBM will improve the decision-making and health care services and protect the doctors and patients rights.